Page 14
CENTRAL ASIAN JOURNAL OF ACADEMIC
RESEARCH
Volume 3, Issue 6, Part 4 Iyun 2025
www.in-academy.uz
CLINICAL AND FUNCTIONAL ASPECTS OF DIABETIC
CARDIOMYOPATHY IN TYPE 2 DIABETES MELLITUS
UNDER EXTREME HEAT CONDITIONS: A COMPREHENSIVE
OVERVIEW OF THERAPEUTIC ADAPTATION
Beshimov A.Ya.
Bukhara State Medical University
https://doi.org/10.5281/zenodo.15755936
ARTICLE INFO
ABSTRACT
Qabul qilindi: 20-Iyun 2025 yil
Ma’qullandi: 24-Iyun 2025 yil
Nashr qilindi: 27-Iyun 2025 yil
Clinical Characteristics of Diabetic Cardiomyopathy
(DCM) in T2DM Patients in Hot Climates Diabetic
cardiomyopathy (DCM), a complication increasingly
encountered in type diabetes mellitus (T2DM),
represents a myocardial pathology independent of
ischemic, hypertensive, or valvular etiologies. Its
pathogenesis involves metabolic, cellular, and structural
alterations culminating in impaired myocardial
relaxation and contraction. Epidemiological surveys
report prevalence rates from 16% to 60% among
diabetic cohorts, contingent upon diagnostic modalities
and regional differences.
KEYWORDS
In arid and thermally extreme
regions, DCM emerges earlier
and evolves more rapidly.
Notably, data from the Bukhara
Cardio Registry (2021) indicate
that DCM accounts for over
40% of all cardiovascular
complications linked to T2DM
in Uzbekistan.
1. Clinical Characteristics of Diabetic Cardiomyopathy (DCM) in T2DM Patients in Hot
Climates
Diabetic cardiomyopathy (DCM), a complication increasingly encountered in type 2
diabetes mellitus (T2DM), represents a myocardial pathology independent of ischemic,
hypertensive, or valvular etiologies. Its pathogenesis involves metabolic, cellular, and
structural alterations culminating in impaired myocardial relaxation and contraction.
Epidemiological surveys report prevalence rates from 16% to 60% among diabetic cohorts,
contingent upon diagnostic modalities and regional differences.
1.1 Climatic Epidemiology
In arid and thermally extreme regions, DCM emerges earlier and evolves more rapidly.
Notably, data from the Bukhara Cardio Registry (2021) indicate that DCM accounts for over
40% of all cardiovascular complications linked to T2DM in Uzbekistan.
1.2 Symptom Manifestation
Patients in hot environments frequently exhibit:
Early and severe dyspnea
Positional and nocturnal breathing difficulty, exacerbated by night-time heat
Pronounced lower limb edema
Onset of symptoms in hot climates precedes those in temperate zones by an average of
5–6 years.
Page 15
CENTRAL ASIAN JOURNAL OF ACADEMIC
RESEARCH
Volume 3, Issue 6, Part 4 Iyun 2025
www.in-academy.uz
1.3 Fluid and Electrolyte Disturbances
Excessive heat exacerbates:
Hyponatremia, leading to impaired myocardial contractility
Hypokalemia, predisposing to ventricular arrhythmias
Hypomagnesemia, increasing risk of QT prolongation and sudden cardiac death
1.4 Sex-Based Susceptibility
Women appear more susceptible to heat-induced DCM destabilization, likely attributed
to endocrine and autonomic variations.
1.5 Clinical Vignette
A 58-year-old woman with long-standing T2DM presented during peak summer with
acute dyspnea, peripheral edema, and palpitations. While left ventricular ejection fraction
(LVEF) remained preserved, Doppler studies showed reduced E/A ratio and electrolyte
abnormalities, consistent with heat-amplified HFpEF.
1.6 Comparative Overview
Parameter
Temperate Zone Hot Climate
Age of Onset
~60 years
~54 years
Dyspnea
Mild/Moderate Severe
Peripheral Edema Minimal
Extensive
Heat Reactivity
Low
High
2. Functional Cardiac Changes in T2DM in Hot Climates
2.1 Diastolic Dysfunction
Often the earliest detectable cardiac abnormality in DCM, diastolic impairment is
aggravated by peripheral vasodilation common in high temperatures. Hallmarks include:
E/A ratio < 1
Elevated E/e’ values
Prolonged deceleration time (>240 ms)
2.2 Preserved Systolic Function with Subclinical Strain Abnormality
Despite normal LVEF, many patients show:
Reduced GLS (<–18%), suggesting latent systolic compromise
Diminished left atrial strain parameters
2.3 Autonomic Nervous System Imbalance
Heightened thermal stress correlates with:
Decreased heart rate variability (HRV)
Elevated resting heart rate
Greater incidence of orthostatic intolerance
2.4 Rhythm Disturbances
Electrolyte perturbations during heatwaves precipitate:
QTc prolongation
Frequent PVCs and short runs of NSVT
Intermittent bundle branch blocks
2.5 Right Ventricular Implication
Page 16
CENTRAL ASIAN JOURNAL OF ACADEMIC
RESEARCH
Volume 3, Issue 6, Part 4 Iyun 2025
www.in-academy.uz
Due to dehydration and pulmonary hypertension, patients often demonstrate:
Reduced TAPSE (<16 mm)
Elevated PASP (>35 mmHg)
2.6 Summary of Functional Metrics
Metric Normal Values Observed in Hot Climate DCM
E/A
1.0–1.5
<1.0
GLS
–18% to –22%
>–18%
SDNN >100 ms
<100 ms
QTc
<450 ms
>470 ms
TAPSE >16 mm
<16 mm
3. Metabolic Dimensions of DCM in Thermal Stress Conditions
3.1 Chronic Hyperglycemia and AGE Accumulation
Persistent high glucose levels induce AGE production, which alters myocardial elasticity
and fosters fibrosis. Elevated thermal stress disrupts insulin dynamics and enhances cortisol
release, worsening glycemic control.
3.2 Insulin Resistance and Lipid Toxicity
Cardiomyocyte insulin resistance reroutes metabolism towards fatty acid oxidation,
with resultant toxic lipid buildup and mitochondrial injury. Reduced physical activity in hot
climates further amplifies these effects.
3.3 Dyslipidemia and Cardiometabolic Risk
Abnormal lipid profiles—low HDL, high triglycerides, and small dense LDL—contribute
to myocardial lipid infiltration. Epidemiological studies from arid regions confirm
exacerbation of lipid parameters during hot seasons.
3.4 Oxidative and Mitochondrial Stress
Thermal load increases ROS generation in mitochondria, leading to mtDNA damage and
ETC dysfunction. Antioxidant defenses become overwhelmed, intensifying cardiac energy
deficits.
3.5 Inflammatory Cascade and Vascular Damage
Heat stress elevates IL-6, TNF-α, and CRP levels, which impair endothelial integrity and
increase thrombotic risk. CIMT and coronary rarefaction are more pronounced in these
patients.
3.6 Overview of Metabolic Alterations
Feature
Mechanism in DCM
Heat-Induced Exacerbation Clinical Impact
Hyperglycemia
AGE/fibrosis
pathway
Insulin absorption delay
Myocardial stiffening
Insulin
Resistance
Impaired
glucose
uptake
Inactivity/cortisol surge
Lipotoxic apoptosis
Dyslipidemia
Myocardial
lipid
deposition
Circadian/behavioral
disruption
Mitochondrial failure
Oxidative Stress Mitochondrial ROS
Heat-induced
metabolic DNA
damage/energy
Page 17
CENTRAL ASIAN JOURNAL OF ACADEMIC
RESEARCH
Volume 3, Issue 6, Part 4 Iyun 2025
www.in-academy.uz
elevation
depletion
Inflammation
Cytokine activation Systemic inflammation
Endothelial dysfunction
4. Strategic Management of DCM under Climatic Heat Burden
4.1 Optimizing Glycemic Control
Medication regimens should reflect heat-induced pharmacokinetic changes:
Metformin use should be cautious during dehydration
SGLT2 inhibitors support cardiovascular protection but require fluid monitoring
GLP-1 receptor agonists reduce inflammation and weight, ideal for sedentary patients
in hot zones
4.2 Tailored Cardiovascular Therapies
Beta-blockers require cautious dosing to avoid thermal intolerance
ACE inhibitors/ARBs necessitate electrolyte and renal monitoring
Spironolactone/eplerenone reduce fibrosis but carry hyperkalemia risk in dehydrated
states
4.3 Antioxidant and Anti-inflammatory Support
Adjunctive agents:
Coenzyme Q10: supports mitochondria
Omega-3s: reduce arrhythmic risk
Statins: dual lipid and vascular benefits
4.4 Fluid and Electrolyte Regulation
ORS with potassium/magnesium advised during summer
Avoidance of aggressive diuretics
Biweekly electrolyte checks in at-risk patients
4.5 Personalized Lifestyle Counseling
Schedule exercise during cooler periods
Ensure climate-controlled environments
Educate on signs of dehydration and heat exhaustion
4.6 Digital Monitoring Integration
Use of CGM and mobile platforms
Heat-adaptive telemedicine
Mobile alerts for environmental risk + glycemic trends
4.7 Therapy Summary Table
Category
Interventions
Heat-Adaptation Considerations
Glycemic Control
Metformin,
SGLT2i,
GLP-1
agonists
Insulin
timing/hydration
adjustments
Cardiac Medications ACEI, BB, MRA
Monitor electrolytes/renal function
Antioxidant Support CoQ10, Omega-3, Statins
ROS mitigation under stress
Hydration
Strategies
ORS, mineral replacement
Prevent hypotension/arrhythmia
Lifestyle
Heat-aware activity/education
Behavioral heat-risk minimization
Page 18
CENTRAL ASIAN JOURNAL OF ACADEMIC
RESEARCH
Volume 3, Issue 6, Part 4 Iyun 2025
www.in-academy.uz
Digital Tools
CGM, apps, teleconsults
Early detection/intervention
Final Considerations and Future Research Priorities
The convergence of type 2 diabetes, cardiomyopathy, and climatic extremes necessitates
a paradigm shift in chronic disease management. This review underscores the imperative to
align therapeutic models with environmental realities.
Key Takeaways:
Diabetic cardiomyopathy manifests earlier and progresses more aggressively in
thermally stressed environments.
Autonomic imbalance, metabolic rigidity, and endothelial vulnerability intensify under
high temperatures.
Multimodal treatment must account for hydration status, drug kinetics, and systemic
inflammation.
Research Agenda:
1.
Conduct climate-specific longitudinal tracking of DCM.
2.
Integrate wearables and smart health platforms for real-time physiological
surveillance.
3.
Innovate thermally stable pharmaceutical formulations.
4.
Implement heat-responsive public health strategies.
5.
Advance personalized care through multi-omics and environmental profiling.
The future of cardiometabolic care in hot climates hinges on precision, prediction, and
prevention—anchored in environmental sensitivity and technological innovation
.
Review:
1. Trachanas K., Sideris S., Aggeli C., Poulidakis E., Gatzoulis K., Tousoulis D., et al. Diabetic
cardiomyopathy: from pathophysiology to treatment. Hellenic J Cardiol.2014;55:411- 421.
PMID: 25243440
2. Lundbaek K. Diabetic angiopathy. A specific vascular disease. Lancet. 1954;263:377-379.
https://doi.org/10.1016/S0140-6736(54)90924-1
3. Rubler S., Dlugash J., Yuceoglu Y.Z., Kumral T., Branwood A.W., Grishman A., et al. New type
of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30:595-
602. https://doi.org/10.1016/0002-9149(72)90595-4
4. Kannel W.B., Hjortland M., Castelli W.P. Role of diabetes in congestive heart failure; the
Framingham study. Am J Cardiol. 1974;34:29-34. https://doi.org/10.1016/0002-
9149(74)90089-7
5. Penpargkul S., Fein F., Sonnenblick E.H., Scheuer J. Depressed cardiac sarcoplasmic reticular
function from diabetic rats. J Mol Cell Cardiol. 1981;13:303-9. https://doi.org/10.1016/0022-
2828(81)90318-7
6. Trost S.U., Belke D.D., Bluhm W.F., Meyer M., Swanson E., Dillmann W.H. Overexpression of
the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic
cardiomyopathy. Diabetes. 2002;51:1166-71. https://doi.org/10.2337/diabetes.51.4.1166
Page 19
CENTRAL ASIAN JOURNAL OF ACADEMIC
RESEARCH
Volume 3, Issue 6, Part 4 Iyun 2025
www.in-academy.uz
1.
Current and Future Therapies. Beyond Glycemic Control. Front Physiol. 2018;9:1514.
https://doi.org/10.3389/fphys.2018.01514
7. Lorenzo-Almorós A., Tuñón J., Orejas M., Cortés M., Egido J., Lorenzo Ó. Diagnostic
approaches for diabetic cardiomyopathy. Cardiovasc Diabetol.
2017;16(1):28.
https://doi.org/10.1186/s12933-017-0506-x
8. Marcinkiewicz A., Ostrowski S., Drzewoski J. Can the onset of heart failure be delayed by
treating
diabetic
cardiomyopathy?
Diabetol
Metab
Syndr.
2017;9:21.
https://doi.org/10.1186/s13098-017-0219-z
9. Lee W.S., Kim J. Diabetic cardiomyopathy: where we are and where we are going. Korean J
Intern Med. 2017;32(3):404- 421. https://doi.org/10.3904/kjim.2016.208.
10. Dillmann W.H. Diabetic Cardiomyopathy. Circ Res. 2019;124(8):1160-1162.
https://doi.org/10.1161/CIRCRESAHA.118.314665
11. Jia G., Hill M.A., Sowers J.R. Diabetic Cardiomyopathy: An Update of Mechanisms
Contributing
to
This
Clinical
Entity.
Circ
Res.
2018;122(4):624-638.
https://doi.org/10.1161/CIRCRESAHA.117.311586
12. Jia G., DeMarco V.G., Sowers J.R. Insulin resistance and hyperinsulinaemia in diabetic
cardiomyopathy.
Nat
Rev
Endocrinol.
2016;12(3):144-153.
https://doi.org/10.1038/nrendo.2015.216
13. Mellor K.M., Bell J.R., Ritchie R.H., Delbridge L.M. Myocardial insulin resistance, metabolic
stress and autophagy in diabetes. Clin Exp Pharmacol Physiol. 2013;40(1):56-61.
https://doi.org/10.1111/j.1440-1681.2012.05738.x
14. Guo R., Nair S. Role of microRNA in diabetic cardiomyopathy: From mechanism to
intervention. Biochim Biophys Acta Mol Basis Dis. 2017;1863(8):2070-2077.
https://doi.org/10.1016/j.bbadis.2017.03.013
16. Konduracka E., Cieslik G., Galicka-Latala D., Rostoff P., Pietrucha A., Latacz P., et al.
Myocardial dysfunction and chronic heart failure in patients with long-lasting type 1 diabetes:
a
7-year
prospective
cohort
study.
Acta
Diabetol.
2013;50(4):597-606.
https://doi.org/10.1007/s00592-013-0455-0
17. Dandamudi S., Slusser J., Mahoney D.W., Redfield M.M., Rodeheffer R.J., Chen H.H. The
prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County,
Minnesota. J Card Fail. 2014;20(5):304-9. https://doi.org/10.1016/j.cardfail.2014.02.007
18. Караваев П. Г., Веклич А. С., Козиолова Н. А. Диабетическая кардиомиопатия:
особенности сердечно-сосудистого ремоделирования. Российский кардиологический
журнал. 2019;24(11):42-47. https://doi.org/10.15829/1560-4071-2019-11-42-47
19. Kenny H.C., Abel E.D. Heart Failure in Type 2 Diabetes Mellitus. Circ Res. 2019;124(1):121-
141. https://doi.org/10.1161/CIRCRESAHA.118.311371
20. Echouffo-Tcheugui J.B., Xu H., DeVore A.D., Schulte P.J., Butler J., Yancy C.W., et al.
Temporal trends and factors associated with diabetes mellitus among patients hospitalized
with heart failure: Findings from Get With The GuidelinesHeart Failure registry. Am Heart J.
2016;182:9-20. https://doi.org/10.1016/j.ahj.2016.07.025
